Digital Biomarker Solution Demonstrates Adherence, User Satisfaction, And Initial Evidence Of Clinical Validity

In Parkinson’s disease studies, challenges exist with current clinical assessments. Digital biomarkers, collected remotely through smartphones or wearables, offer a solution. Researchers can gain insights into treatment response and disease progression by objectively gathering patient data frequently and without in-person visits.

In a clinical study for early Parkinson's disease, which involved 316 participants, digital biomarkers, including motor sub-scores and digital composite scores, were implemented, and the results indicated the sensitivity of digital measurements in detecting disease progression.¹

Access the white paper below to learn more about the benefits of digital biomarkers.

^{(1) Pagano, G., et al. N Engl J Med 2022;387:421-32}

^{(2) Lipsmeier, F., et al. Sci Rep 12, 12081}

^{Disclaimer: The Roche Digital Biomarker Solution for Parkinson’s disease is intended to collect, store and process digital clinical data to support exploratory research in clinical trials. This solution is not meant to be used for diagnosis and treatment decision making for individual patients.}